<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">31403352</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>02</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Development and characterization of an enterovirus 71 (EV71) virus-like particles (VLPs) vaccine produced in <i>Pichia pastoris</i>.</ArticleTitle><Pagination><StartPage>1602</StartPage><EndPage>1610</EndPage><MedlinePgn>1602-1610</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2019.1649554</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) is one of the major causative agents for hand, foot and mouth disease (HFMD) in children. Although there are three inactivated virus-based HFMD vaccines licensed in China, alternative approaches have been taken to produce an effective and safer vaccine that is easier to manufacture in large scale. Among these, a virus-like particles (VLPs) based EV71 vaccine is under active development. For this purpose, an efficient methodology for the production of EV71-VLPs by recombinant technology is needed. We here report the construction and expression of the P1 and 3C genes of EV71 in <i>Pichia pastoris</i> for producing VLP-based EV71 vaccine antigen with a high yield and simple manufacturing process. Based on codon-optimized P1 and 3C genes, EV71-VLPs were efficiently expressed in <i>Pichia pastoris</i> system, and the expression level reached 270 mg/L. Biochemical and biophysical analyses showed that the produced EV71-VLPs consisted of processed VP0, VP1, and VP3 present as ~35nm spherical particles. The immune response as a function of EV71-VLPs and adjuvant dose ratio was investigated for vaccine development. Immunization with EV71-VLPs of 1-5 &#xb5;g/dose and adjuvant of 225 &#xb5;g/dose induced robust neutralizing antibody responses in mice and provided effective protection against lethal challenge in both maternally transferred antibody and passive transfer protection mouse models. Therefore, the yeast produced EV71-VLPs antigen is a promising candidate for the development of a vaccine against HFMD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Zhijian</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-5143-0890</Identifier><AffiliationInfo><Affiliation>Shanghai Zerun Biotechnology Co., Ltd , Shanghai, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus Vaccines, National Institutes for Food and Drug Control (NIFDC) , Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaoliang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Shanghai Zerun Biotechnology Co., Ltd , Shanghai, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Likang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Shanghai Zerun Biotechnology Co., Ltd , Shanghai, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Shanghai Zerun Biotechnology Co., Ltd , Shanghai, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yuanxiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shanghai Zerun Biotechnology Co., Ltd , Shanghai, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Xinxing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Shanghai Zerun Biotechnology Co., Ltd , Shanghai, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Shanghai Zerun Biotechnology Co., Ltd , Shanghai, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Chenliang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Shanghai Zerun Biotechnology Co., Ltd , Shanghai, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Xianfang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Shanghai Zerun Biotechnology Co., Ltd , Shanghai, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ge</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Shanghai Zerun Biotechnology Co., Ltd , Shanghai, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Jiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Shanghai Zerun Biotechnology Co., Ltd , Shanghai, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus Vaccines, National Institutes for Food and Drug Control (NIFDC) , Beijing, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Shanghai Zerun Biotechnology Co., Ltd , Shanghai, PR China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000676904">Komagataella pastoris</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004718" MajorTopicYN="N">Saccharomycetales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058425" MajorTopicYN="Y">Vaccines, Virus-Like Particle</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterovirus 71</Keyword><Keyword MajorTopicYN="N">Pichia pastoris</Keyword><Keyword MajorTopicYN="N">hand foot and mouth disease</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword><Keyword MajorTopicYN="N">virus-like particles</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31403352</ArticleId><ArticleId IdType="pmc">PMC7482752</ArticleId><ArticleId IdType="doi">10.1080/21645515.2019.1649554</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chong P, Hsieh SY, Liu CC, Chou AH, Chang JY, Wu SC, Liu SJ, Chow YH, Su IJ, Klein M.. Production of EV71 vaccine candidates. Hum Vaccin Immunother. 2012;8(12):1775&#x2013;83. doi:10.4161/hv.21739.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.21739</ArticleId><ArticleId IdType="pmc">PMC3656065</ArticleId><ArticleId IdType="pubmed">22992566</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Liao QH, Ooi MH, Cowling BJ, Chang ZR, Wu P, Liu FF, Li Y, Luo L, Yu SB, et al. Epidemiology of recurrent hand, foot and mouth disease, China, 2008&#x2013;2015. Emerg Infect Dis. 2018;24(3):432&#x2013;42. doi:10.3201/eid2403.171303.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2403.171303</ArticleId><ArticleId IdType="pmc">PMC5823341</ArticleId><ArticleId IdType="pubmed">29460747</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh WM, Bogich T, Siegel K, Jin J, Chong EY, Tan CY, Chen MIC, Horby P, Cook AR. The epidemiology of hand, foot and mouth disease in Asia a systematic review and analysis. Pediatr Infect Dis J. 2016;35(10):E285&#x2013;E300. doi:10.1097/inf.0000000000001242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/inf.0000000000001242</ArticleId><ArticleId IdType="pmc">PMC5130063</ArticleId><ArticleId IdType="pubmed">27273688</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang PC, Chen SC, Chen KT. The current status of the disease caused by enterovirus 71 infections: epidemiology, pathogenesis, molecular epidemiology, and vaccine development. Int J Environ Res Public Health. 2016;13(9):890. doi:10.3390/ijerph13090890.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph13090890</ArticleId><ArticleId IdType="pmc">PMC5036723</ArticleId><ArticleId IdType="pubmed">27618078</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang S, Suh SI, Ha SM, Byeon JH, Eun BL, Lee YH, Seo HS, Eun SH, Seol HY. Enterovirus 71-related encephalomyelitis: usual and unusual magnetic resonance imaging findings. Neuroradiology. 2012;54(3):239&#x2013;45. doi:10.1007/s00234-011-0921-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00234-011-0921-8</ArticleId><ArticleId IdType="pubmed">21861081</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng KF, Chen LL, Huang PN, Shih SR. Neural pathogenesis of enterovirus 71 infection. Microbes and infection/Institut Pasteur. 2010;12(7):505&#x2013;10. doi:10.1016/j.micinf.2010.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2010.03.006</ArticleId><ArticleId IdType="pubmed">20348010</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan Z-K, Jin H, Li J-X, Yao X-J, Zhou Y, Zhang X-F, Zhu F-C. Disease burden of enterovirus 71 in rural central China: a community-based survey. Hum Vaccin Immunother. 2015;11(10):2400&#x2013;05. doi:10.1080/21645515.2015.1059980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1059980</ArticleId><ArticleId IdType="pmc">PMC4635911</ArticleId><ArticleId IdType="pubmed">26158689</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Zeng G, Chu K, Zhang J, Han W, Zhang Y, Li J, Zhu F. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: a further observation. Hum Vaccin Immunother. 2018;14(6):1517&#x2013;23. doi:10.1080/21645515.2018.1442997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1442997</ArticleId><ArticleId IdType="pmc">PMC6037439</ArticleId><ArticleId IdType="pubmed">29482422</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei M, Meng F, Wang S, Li J, Zhang Y, Mao Q, Hu Y, Liu P, Shi N, Tao H, et al. 2-year efficacy, immunogenicity, and safety of vigoo enterovirus 71 vaccine in healthy Chinese children: a randomized open-label study. J Infect Dis. 2017;215(1):56&#x2013;63. doi:10.1093/infdis/jiw502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw502</ArticleId><ArticleId IdType="pubmed">28077584</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Kong Y, Jiang Z, Li C, Wang L, Xia J. Comprehensive safety assessment of a human inactivated diploid enterovirus 71 vaccine based on a phase III clinical trial. Hum Vaccin Immunother. 2016;12(4):922&#x2013;30. doi:10.1080/21645515.2015.1115934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1115934</ArticleId><ArticleId IdType="pmc">PMC4962949</ArticleId><ArticleId IdType="pubmed">26837471</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell CJ, Howard CR, Murphy FA, editors. Chapter 11 - vaccines and vaccination. In: Burrell CJ, Howard CR, Murphy FA, editors. Fenner and White&#x2019;s medical virology. 5th ed. London (UK): Academic Press; 2017. p. 155&#x2013;67. doi:10.1016/B978-0-12-375156-0.00011-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-375156-0.00011-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine. 2012;31(1):58&#x2013;83. doi:10.1016/j.vaccine.2012.10.083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.10.083</ArticleId><ArticleId IdType="pmc">PMC7115575</ArticleId><ArticleId IdType="pubmed">23142589</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad M, Hirz M, Pichler H, Schwab H. Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production. Appl Microbiol Biotechnol. 2014;98(12):5301&#x2013;17. doi:10.1007/s00253-014-5732-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-014-5732-5</ArticleId><ArticleId IdType="pmc">PMC4047484</ArticleId><ArticleId IdType="pubmed">24743983</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Dai WL, Zhang C, Zhou Y, Xiong P, Wang SX, Ye XH, Liu QW, Zhou DM, Huang Z. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg Microbes Infect. 2018;7:94. doi:10.1038/s41426-018-0094-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0094-1</ArticleId><ArticleId IdType="pmc">PMC5959873</ArticleId><ArticleId IdType="pubmed">29777102</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmons B, Lim PY, Djurup R, Cardosa J. Non-clinical safety assessment of repeated intramuscular administration of an EV-A71 VLP vaccine in rabbits. Vaccine. 2018;36(45):6623&#x2013;30. doi:10.1016/j.vaccine.2018.09.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.09.062</ArticleId><ArticleId IdType="pubmed">30293762</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun SY, Gao F, Mao QY, Shao J, Jiang LP, Liu DW, Wang YP, Yao X, Wu X, Sun B, et al. Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice. Hum Vaccin Immunother. 2015;11(10):2406&#x2013;13. doi:10.1080/21645515.2015.1053675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1053675</ArticleId><ArticleId IdType="pmc">PMC4635907</ArticleId><ArticleId IdType="pubmed">26036916</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Huang JH, Lai CW, Sheng HC, Shih SR, Ho MS, Hu YC. Expression, purification and characterization of enterovirus-71 virus-like particles. World J Gastroenterol. 2006;12(6):921&#x2013;27. doi:10.3748/wjg.v12.i6.921.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v12.i6.921</ArticleId><ArticleId IdType="pmc">PMC4066158</ArticleId><ArticleId IdType="pubmed">16521221</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal, challenge. Vaccine. 2008;26(15):1855&#x2013;62. doi:10.1016/j.vaccine.2008.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku ZQ, Liu QW, Ye XH, Cai YC, Wang XL, Shi JP, Li DP, Jin X, An WQ, Huang Z. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine. 2014;32(34):4296&#x2013;303. doi:10.1016/j.vaccine.2014.06.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.06.025</ArticleId><ArticleId IdType="pubmed">24950363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim PY, Hickey AC, Jamiluddin MF, Hamid S, Kramer J, Santos R, Bossart KN, Cardosa MJ. Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates. Vaccine. 2015;33(44):6017&#x2013;24. doi:10.1016/j.vaccine.2015.05.108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.05.108</ArticleId><ArticleId IdType="pubmed">26271825</ArticleId></ArticleIdList></Reference><Reference><Citation>Somasundaram B, Chang C, Fan YY, Lim PY, Cardosa J, Lua L. Characterizing Enterovirus 71 and Coxsackievirus A16 virus-like particles production in insect cells. Methods. 2016;95:38&#x2013;45. doi:10.1016/j.ymeth.2015.09.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2015.09.023</ArticleId><ArticleId IdType="pubmed">26410190</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CY, Chen CY, Lin SY, Chung YC, Chiu HY, Chi WK, Lin YL, Chiang BL, Chen WJ, Hu YC. Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield. Vaccine. 2010;28(43):6951&#x2013;57. doi:10.1016/j.vaccine.2010.08.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.08.052</ArticleId><ArticleId IdType="pubmed">20797455</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Ku ZQ, Liu QW, Wang XL, Chen T, Ye XH, Li DP, Jin X, Huang Z. High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. Vaccine. 2015;33(20):2335&#x2013;41. doi:10.1016/j.vaccine.2015.03.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.03.034</ArticleId><ArticleId IdType="pubmed">25820068</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HY, Han JF, Qin CF, Chen R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine. 2013;31(32):3281&#x2013;87. doi:10.1016/j.vaccine.2013.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.05.019</ArticleId><ArticleId IdType="pubmed">23726823</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Li N, Yu X, Yao X, Li F, Lu F, Zhuang H, Liang Z, Wang J. Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch Virol. 2012;157(1):37&#x2013;41. doi:10.1007/s00705-011-1136-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-011-1136-3</ArticleId><ArticleId IdType="pubmed">21984267</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Mao C, Ma S, Wang X, Sun Z, Yi Y, Guo M, Shen X, Sun L, Bi S. Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides. Biochem Biophys Res Commun. 2009;390(4):1126&#x2013;28. doi:10.1016/j.bbrc.2009.09.103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2009.09.103</ArticleId><ArticleId IdType="pubmed">19799860</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z, Mao Q, Gao Q, Li X, Dong C, Yu X, Yao X, Li F, Yin W, Li Q, et al. Establishing China&#x2019;s national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine. 2011;29(52):9668&#x2013;74. doi:10.1016/j.vaccine.2011.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.10.018</ArticleId><ArticleId IdType="pubmed">22015395</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Yan K, Feng Y, Huang X, Ku Z, Cai Y, Liu F, Shi J, Huang Z. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine. 2012;30(47):6642&#x2013;48. doi:10.1016/j.vaccine.2012.08.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.08.071</ArticleId><ArticleId IdType="pubmed">22959985</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao QY, Wang YP, Bian LL, Xu M, Liang ZL. EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases. Emerg Microbes Infect. 2016;5(7):e75. doi:10.1038/emi.2016.73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2016.73</ArticleId><ArticleId IdType="pmc">PMC5141264</ArticleId><ArticleId IdType="pubmed">27436364</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Guo MS, Lin FH, Hsiao KN, Chang KH, Chou AH, Wang YC, Chen YC, Yang CS, Chong PC. Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS One. 2011;6(5):e20005. doi:10.1371/journal.pone.0020005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020005</ArticleId><ArticleId IdType="pmc">PMC3094384</ArticleId><ArticleId IdType="pubmed">21603631</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SY, Chiu HY, Chiang BL, Hu YC. Development of EV71 virus-like particle purification processes. Vaccine. 2015;33(44):5966&#x2013;73. doi:10.1016/j.vaccine.2015.04.077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.04.077</ArticleId><ArticleId IdType="pubmed">25939279</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012;19(4):424&#x2013;29. doi:10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong CH, Liu LD, Zhao HL, Wang JJ, Liao Y, Zhang XM, Na RX, Liang Y, Wang LC, Li QH. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine. 2011;29(37):6269&#x2013;75. doi:10.1016/j.vaccine.2011.06.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.06.044</ArticleId><ArticleId IdType="pubmed">21722686</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu LD, Mo ZJ, Liang ZL, Zhang Y, Li RC, Ong KC, Wong KT, Yang EX, Che YC, Wang JJ, et al. Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: a report of further observations. BMC Med. 2015;13:226. doi:10.1186/s12916-015-0448-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-015-0448-7</ArticleId><ArticleId IdType="pmc">PMC4574357</ArticleId><ArticleId IdType="pubmed">26381232</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YJ, Meng FY, Mao QY, Li JX, Wang H, Liang ZL, Zhang YT, Gao F, Chen QH, Hu YM, et al. Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial. Hum Vaccin Immunother. 2014;10(5):1366&#x2013;72. doi:10.4161/hv.28397.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.28397</ArticleId><ArticleId IdType="pmc">PMC4896521</ArticleId><ArticleId IdType="pubmed">24633366</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Ye X, Huang X, Cai Y, Liu Q, Li Y, Su Z, Huang Z. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS One. 2013;8(2):e57601. doi:10.1371/journal.pone.0057601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057601</ArticleId><ArticleId IdType="pmc">PMC3579802</ArticleId><ArticleId IdType="pubmed">23451250</ArticleId></ArticleIdList></Reference><Reference><Citation>Bek EJ, Hussain KM, Phuektes P, Kok CC, Gao Q, Cai F, Gao Z, McMinn PC. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine. 2011;29(29&#x2013;30):4829&#x2013;38. doi:10.1016/j.vaccine.2011.04.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.070</ArticleId><ArticleId IdType="pubmed">21550375</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y-L, Yu C-I, Hu Y-C, Tsai T-J, Kuo Y-C, Chi W-K, Lin A-N, Chiang B-L. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine. 2012;30(7):1305&#x2013;12. doi:10.1016/j.vaccine.2011.12.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.12.081</ArticleId><ArticleId IdType="pubmed">22214888</ArticleId></ArticleIdList></Reference><Reference><Citation>Vecchi S, Bufali S, Skibinski DA, O&#x2019;Hagan DT, Singh M. Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations. J Pharm Sci. 2012;101(1):17&#x2013;20. doi:10.1002/jps.22759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.22759</ArticleId><ArticleId IdType="pubmed">21918987</ArticleId></ArticleIdList></Reference><Reference><Citation>Di, Pasquale A, Preiss S, Tavares Da Silva F, Garcon N. Vaccine adjuvants: from 1920 to 2015 and Beyond. Vaccines (Basel). 2015;3(2):320&#x2013;43. doi:10.3390/vaccines3020320.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines3020320</ArticleId><ArticleId IdType="pmc">PMC4494348</ArticleId><ArticleId IdType="pubmed">26343190</ArticleId></ArticleIdList></Reference><Reference><Citation>He P, Zou Y, Hu Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum Vaccin Immunother. 2015;11(2):477&#x2013;88. doi:10.1080/21645515.2014.1004026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2014.1004026</ArticleId><ArticleId IdType="pmc">PMC4514166</ArticleId><ArticleId IdType="pubmed">25692535</ArticleId></ArticleIdList></Reference><Reference><Citation>HogenEsch H, O&#x2019;Hagan DT, Fox CB. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines. 2018;3:51. doi:10.1038/s41541-018-0089-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-018-0089-x</ArticleId><ArticleId IdType="pmc">PMC6180056</ArticleId><ArticleId IdType="pubmed">30323958</ArticleId></ArticleIdList></Reference><Reference><Citation>Doria-Rose NA, Joyce MG. Strategies to guide the antibody affinity maturation process. Curr Opin Virol. 2015;11:137&#x2013;47. doi:10.1016/j.coviro.2015.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2015.04.002</ArticleId><ArticleId IdType="pmc">PMC4456294</ArticleId><ArticleId IdType="pubmed">25913818</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu LD, Zhang Y, Wang JJ, Zhao HL, Jiang L, Che YC, Shi HJ, Li RC, Mo ZJ, Huang T, et al. Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS One. 2013;8(1):e54451. doi:10.1371/journal.pone.0054451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0054451</ArticleId><ArticleId IdType="pmc">PMC3553120</ArticleId><ArticleId IdType="pubmed">23372725</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>